These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12807368)

  • 21. The economics of lung cancer management in Canada.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Lung Cancer; 1996 Feb; 14(1):19-29. PubMed ID: 8696718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
    Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resource implications of palliative chemotherapy for ovarian cancer.
    Doyle C; Stockler M; Pintilie M; Panesar P; Warde P; Sturgeon J; Oza AM
    J Clin Oncol; 1997 Mar; 15(3):1000-7. PubMed ID: 9060539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost of care for lung cancer in the first year after diagnosis in Iran.
    Mohagheghi MA; Mousavi-Jarrahi Y; Mosavi-Jarrahi A
    Asian Pac J Cancer Prev; 2011; 12(4):1013-5. PubMed ID: 21790243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
    Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
    Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The cost components of the management strategies for lung cancer in France].
    Vergnenègre A; Molinier L; Combescure C; Daurès JP; Housset B; Chouaid C
    Rev Mal Respir; 2004 Jun; 21(3 Pt 1):501-10. PubMed ID: 15292842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
    Garg S; Gielda BT; Kiel K; Turian JV; Fidler MJ; Batus M; Bonomi P; Sher DJ
    Pract Radiat Oncol; 2014; 4(5):342-348. PubMed ID: 25194104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
    Vergnenegre A; Corre R; Berard H; Paillotin D; Dujon C; Robinet G; Crequit J; Bota S; Thomas P; Chouaid C;
    J Thorac Oncol; 2011 Jan; 6(1):161-8. PubMed ID: 21150465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment cost of non-small cell lung cancer in three European countries: comparisons across France, Germany, and England using administrative databases.
    McGuire A; Martin M; Lenz C; Sollano JA
    J Med Econ; 2015; 18(7):525-32. PubMed ID: 25802950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
    Cromwell I; van der Hoek K; Malfair Taylor SC; Melosky B; Peacock S
    Lung Cancer; 2012 Jun; 76(3):472-7. PubMed ID: 22226627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.
    Hornberger J; Hirsch FR; Li Q; Page RD
    Lung Cancer; 2015 May; 88(2):223-30. PubMed ID: 25804732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of non-small-cell lung cancer: the Chinese experience in a general teaching hospital.
    Chen YM; Chao JY; Tsai CM; Shiau CY; Liang MJ; Yen SH; Perng RP
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jun; 63(6):459-66. PubMed ID: 10925536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hospitalization costs of lung cancer diagnosis in Turkey: Is there a difference between histological types and stages?
    Türk M; Yıldırım F; Yurdakul AS; Öztürk C
    Tuberk Toraks; 2016 Dec; 64(4):263-268. PubMed ID: 28393715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors for post-recurrence survival in patients with completely resected Stage I non-small-cell lung cancer.
    Song IH; Yeom SW; Heo S; Choi WS; Yang HC; Jheon S; Kim K; Cho S
    Eur J Cardiothorac Surg; 2014 Feb; 45(2):262-7. PubMed ID: 23811122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer.
    Lanni TB; Grills IS; Kestin LL; Robertson JM
    Am J Clin Oncol; 2011 Oct; 34(5):494-8. PubMed ID: 20805737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort.
    Hillner BE; McDonald MK; Desch CE; Smith TJ; Penberthy LT; Maddox P; Retchin SM
    J Clin Oncol; 1998 Apr; 16(4):1420-4. PubMed ID: 9552046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
    Klein R; Muehlenbein C; Liepa AM; Babineaux S; Wielage R; Schwartzberg L
    J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer.
    Leighl NB; Shepherd FA; Kwong R; Burkes RL; Feld R; Goodwin PJ
    J Clin Oncol; 2002 Mar; 20(5):1344-52. PubMed ID: 11870178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lung cancer management in limited resource settings: guidelines for appropriate good care.
    Macbeth FR; Abratt RP; Cho KH; Stephens RJ; Jeremic B;
    Radiother Oncol; 2007 Feb; 82(2):123-31. PubMed ID: 17239979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.